Update on long-term stimulant medication treatment of attention-deficit hyperactivity disorder.

W. Barbaresi

DOI: https://doi.org/10.1097/DBP.0000000000000084

2014-09-01

Abstract:William J. Barbaresi, MD In the 8 years since the publication of the study describing long-term stimulant medication treatment of attention-deficit hyperactivity disorder (ADHD) from early childhood through adolescence among children from a population-based birth cohort, there have been a number of studies that have added to our understanding and capacity to treat ADHD, the most common neurodevelopmental disorder in childhood.1–3 The original study demonstrated that nearly 80% of children with ADHD were treated with stimulant medication at some time during childhoodadolescence; treatment effectiveness was comparable with efficacy rates from previous clinical trials, and side effects occurred at an acceptable rate. However, treatment duration averaged just over 3 years. The imperative to ensure long-term treatment of ADHD has increased as studies, including additional reports from an adult follow-up of this cohort, have demonstrated the chronicity and adverse impact of ADHD from childhood through adulthood.4,5 Recent reports have demonstrated that ADHD is being diagnosed and treated at rates that continue to increase.3 Nevertheless, as in the original study, many children with ADHD continue to go untreated, and, perhaps most disturbing, the evidence continues to suggest that treatment is not continued into the highrisk adolescent and early adult years despite the known chronicity of ADHD and its attendant impact on adolescents and young adults.3,6 A number of new long-acting stimulant and nonstimulant medications have become available in recent years, and it is hoped that these treatment options, along with increased understanding about the chronicity of ADHD, will lead to improved rates of long-term treatment and improved outcomes (see http://www.webmd.com/addadhd/adhd-medication-chart for a list of currently available medications). UPDATES Rate of ADHD Diagnosis and Treatment in Childhood The issue of long-term treatment of ADHD can only be understood in the context of the epidemiology of the disorder, particularly given the high prevalence of ADHD because the US public continues to express concern about rates at which stimulant medications are prescribed to children. In a recent CDC report describing rates of parent-reported ADHD diagnosis among US children aged 4 to 17 years from 2003 to 2011, prevalence of having ever received an ADHD diagnosis increased from 7.8% to 11.0%.3 The reported 11.0% prevalence rate equates to 6.4 million children having received an ADHD diagnosis, whereas 8.0% (5.1 million) were reported to have a current ADHD diagnosis. However, among those with a current ADHD diagnosis, only 69.0% were taking ADHD medication (6.1% or 3.5 million children). This figure is somewhat lower than the 77.8% stimulant treatment rate in the 1976–1980 Rochester, MN birth cohort during childhood.1